The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer

The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer

Abstract Prostate cancer (PCa) and Type 2 diabetes (T2D) often co-occur, yet their relationship remains elusive. While some studies suggest that T2D lowers PCa risk, others report conflicting data. This study investigates the effects of peroxisome proliferator-activated receptor (PPAR) agonists Beza...

Full description

Saved in:
Bibliographic Details
Main Authors: Emine Atas, Kerstin Berchtold, Michaela Schlederer, Sophie Prodinger, Felix Sternberg, Perla Pucci, Christopher Steel, Jamie D. Matthews, Emily R. James, Cécile Philippe, Karolína Trachtová, Ali A. Moazzami, Nastasiia Artamonova, Felix Melchior, Torben Redmer, Gerald Timelthaler, Elena E. Pohl, Suzanne D. Turner, Isabel Heidegger, Marcus Krueger, Ulrike Resch, Lukas Kenner
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Molecular Cancer
Subjects:
Metabolic rewiring
Type 2 diabetes mellitus (T2DM)
PPAR agonists
Cancer therapy
Oxygen consumption rate
Extracellular acidification
Online Access:https://doi.org/10.1186/s12943-025-02320-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12943-025-02320-y

Similar Items